The DMX-200 trial design
The trial design of DMX-200 in CKD was a single arm, open-label trial in adult patients with CKD (exhibiting proteinuria). The patients on the Phase 2a clinical study suffered from CKD of all causes, and 27 patients passed screening and received at least one dose of DMX-200. Patients dosed were diagnosed with diabetic nephropathy (10), IgA nephropathy (6), and other proteinuric diseases (11). DMX-200 was given to patients orally during the trial, and each patient received a dose three times per day.
The hints have been given.. looking forward to the full release of results in early Nov!!
The DMX-200 trial design The trial design of DMX-200 in CKD was...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.015(3.70%) |
Mkt cap ! $220.0M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 40.5¢ | 38.5¢ | $529.7K | 1.351M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 233623 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 19864 | 6 |
View Market Depth
| Last trade - 11.52am 18/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |